Exact Sciences Corporation (EXAS)

NASDAQ: EXAS · IEX Real-Time Price · USD
50.38
-1.57 (-3.02%)
At close: May 17, 2024, 4:00 PM
50.60
+0.22 (0.44%)
After-hours: May 17, 2024, 7:47 PM EDT
-3.02%
Market Cap 9.32B
Revenue (ttm) 2.53B
Net Income (ttm) -240.23M
Shares Out 184.53M
EPS (ttm) -1.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,631,801
Open 51.95
Previous Close 51.95
Day's Range 50.35 - 51.95
52-Week Range 50.42 - 100.77
Beta 1.26
Analysts Strong Buy
Price Target 90.42 (+79.48%)
Earnings Date May 8, 2024

About EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Co... [Read more]

Sector Healthcare
Founded 1995
Employees 6,600
Stock Exchange NASDAQ
Ticker Symbol EXAS
Full Company Profile

Financial Performance

In 2023, Exact Sciences's revenue was $2.50 billion, an increase of 19.93% compared to the previous year's $2.08 billion. Losses were -$204.15 million, -67.26% less than in 2022.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for EXAS stock is "Strong Buy." The 12-month stock price forecast is $90.42, which is an increase of 79.48% from the latest price.

Price Target
$90.42
(79.48% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences' Oncotype DX® Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer Patients

LONDON--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK's National Institute for Health and Care Excellence (NICE) has recomme...

8 days ago - Business Wire

Exact Sciences Announces First-Quarter 2024 Results

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $638 million for...

9 days ago - Business Wire

Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW® 2024

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences to present strategies and advancements for improving colorectal cancer screening rates and outcomes during Digestive Disease Week® 2024.

11 days ago - Business Wire

Exact Sciences to Participate in May Investor Conference

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the follow...

17 days ago - Business Wire

Exact Sciences Names Aaron Bloomer as New Chief Financial Officer

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer ...

4 weeks ago - Business Wire

Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS) (the “Company”), a leading provider of cancer screening and diagnostic tests, today announced that on April 10, 2024 it entered into...

5 weeks ago - Business Wire

Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-...

5 weeks ago - Business Wire

Exact Sciences Schedules First Quarter 2024 Earnings Call

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 20...

5 weeks ago - Business Wire

Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment

ROCHESTER, Minn. & MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences and Mayo Clinic advance precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients.

6 weeks ago - Business Wire

Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, in collaboration with Mayo Clinic Comprehensive Cancer Center, reporte...

7 weeks ago - Business Wire

Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2024 Gallup Exceptional Workplace ...

7 weeks ago - Business Wire

The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced online publication of the BLUE-C study results in The ...

2 months ago - Business Wire

Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with iconic pro basketball all-star and Kentucky legend ...

2 months ago - Business Wire

Exact Sciences Launches Riskguard™ Hereditary Cancer Test in the United States

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard™ hereditary cancer test in the United Sta...

2 months ago - Business Wire

Exact Sciences to Participate in March Investor Conference

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the follow...

2 months ago - Business Wire

Exact Sciences Announces Fourth Quarter 2023 Results

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $647 million for...

3 months ago - Business Wire

Exact Sciences Schedules Fourth Quarter 2023 Earnings Call

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2...

3 months ago - Business Wire

Geneoscopy Files Inter Partes Review Petition Challenging Exact Sciences' Patent

ST. LOUIS, Mo.--(BUSINESS WIRE)--Geneoscopy Files Inter Partes Review Petition Challenging Exact Sciences' Patent.

4 months ago - Business Wire

Exact Sciences Announces Preliminary Fourth Quarter 2023 Results

Anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion, submits next-generation Cologuard® to FDA Announces Chief Financial Officer succession plan Highlighted anno...

4 months ago - PRNewsWire

Exact Sciences to participate in J.P. Morgan Healthcare Conference

MADISON, Wis. , Jan. 2, 2024 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate ...

4 months ago - PRNewsWire

Election noise may make pharmaceutical stocks 'untenable' for investors, says Mizuho's Jared Holz

Jared Holz, Mizuho healthcare sector specialist, joins 'The Exchange' to discuss the 2024 outlook for health care, which stocks to buy in the new year, and more.

Other symbols: BIIBMRKTEVA
5 months ago - CNBC Television

Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings

MADISON, Wis. , Dec. 7, 2023 /PRNewswire/ -- Exact Sciences, a leading provider of cancer screening and diagnostic tests, announced today that it awarded $1.3 million to 23 organizations through its F...

5 months ago - PRNewsWire

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

Updated TAILORx follow-up data showing the integration of clinico-pathologic criteria and Recurrence Score® results to refine distant recurrence risk estimates New concordance analysis supporting the ...

6 months ago - PRNewsWire

Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy

Company asserts that Geneoscopy infringed patented technology central to its Cologuard colorectal cancer screening test MADISON, Wis. , Nov. 17, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS...

6 months ago - PRNewsWire

Exact Sciences Announces Third-Quarter 2023 Results

Reports record revenue, delivers more than a million test results, raises full-year guidance Third -quarter 2023 highlights Total third quarter revenue of $628 million, an increase of 20%, or 23% on a...

7 months ago - PRNewsWire